# OnCo record gamida-cell (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/gamida-cell/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "gamida-cell" ;
  schema:name "Gamida Cell"@en ;
  schema:alternateName "Gamida Cell Ltd."@en ;
  schema:description "Gamida Cell developed omidubicel, the nicotinamide-expanded cord blood therapy approved by the FDA in 2023 to speed neutrophil recovery after transplant in patients with blood cancers."@en ;
  schema:url <https://onco.cc/companies/gamida-cell/>, <https://www.gamida-cell.com/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.gamida-cell.com/>, <https://www.fda.gov/news-events/press-announcements/fda-approves-cell-therapy-patients-blood-cancers-reduce-risk-infection-following-stem-cell>, <https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=gamida+cell&type=&dateb=&owner=include&count=40> ;
  onco:tag "fda-oce-applicant" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/mds/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:drugs <https://onco.cc/drugs/omidubicel/>, <https://onco.cc/drugs/motixafortide/> ;
  onco:companies <https://onco.cc/companies/biolinerx/> .